91 related articles for article (PubMed ID: 7293181)
1. [Chemotherapy of non-Hodgkin lymphoma by the COP schedule].
Krajewska B; Solska E; Dziewulska-Bokiniec A
Wiad Lek; 1981 May; 34(10):815-9. PubMed ID: 7293181
[No Abstract] [Full Text] [Related]
2. [Results of treatment of advanced cases of non-Hodgkin's-lymphoma (author's transl)].
Kotlarek-Haus S; Nowicka J; Gabryś K; Starzyk H; Becker M; Kaiser A; Hinrle Z
Przegl Lek; 1979; 36(7):567-71. PubMed ID: 504706
[No Abstract] [Full Text] [Related]
3. [VCP therapy for non-Hodgkin's lymphoma advanced more than stage IIB].
Kuraishi Y; Ozeki H; Takasaki N; Mashizu N; Nagamine D; Usui N; Yamazaki H; Nakamura T; Aiba K; Yokoyama K
Rinsho Ketsueki; 1984 Nov; 25(11):1731-7. PubMed ID: 6543455
[No Abstract] [Full Text] [Related]
4. A comparative study with COP and COP-Bleo combination chemotherapy in advanced (non-Hodgkin's) lymphomas.
Kaku K; Inoue M; Fujii S; Ishida Y; Hiroshige Y; Shinohara K; Nakashima K; Matsumoto N; Kaneko T
Nihon Ketsueki Gakkai Zasshi; 1983 Jul; 46(4):940-6. PubMed ID: 6195877
[No Abstract] [Full Text] [Related]
5. Evaluation of two combination chemotherapies in previously untreated non Hodgkin's lymphoma.
Somoza N; Pavlovsky S; Suárez A; Morgenfeld M; Besuschio SC; Bezares R; Quiroga Micheo E; Lein JM; De María H
Medicina (B Aires); 1981; 41 Suppl():35-43. PubMed ID: 7345350
[No Abstract] [Full Text] [Related]
6. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
7. [Preliminary analysis of results of chemotherapy in patients with proliferative disease of the lymphatic system with the exclusion of Hodgkin's disease using vincristine, cyclophosphamide and prednisone].
Zelechowska JA; Leszczyk C; Madej G; Pieńkowska F; Nozdryn-Plotnicki B
Pol Tyg Lek; 1977 Aug; 32(34):1329-31. PubMed ID: 905177
[No Abstract] [Full Text] [Related]
8. [Biweekly CHOP-E chemotherapy for aggressive non-Hodgkin's lymphoma].
Hayashi T; Takahashi T; Mihara M; Shimizu H; Tsukuda H; Kobayashi T; Adachi M; Hinoda Y; Aoki S; Mori M; Tsujisaki M; Imai K
Gan To Kagaku Ryoho; 1997 May; 24(7):889-91. PubMed ID: 9170532
[No Abstract] [Full Text] [Related]
9. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
[TBL] [Abstract][Full Text] [Related]
10. [Polychemotherapy of lymphosarcoma by the COP program].
Abdullaev RA; Poddubnaia IV; Shramko AF
Sov Med; 1984; (7):103-6. PubMed ID: 6385297
[No Abstract] [Full Text] [Related]
11. [Biweekly cyclophosphamide, epirubicin, vincristine and prednisolone (CEOP) chemotherapy for the elderly patients with aggressive non-Hodgkin's lymphoma. Tochigi Malignant Lymphoma Study Group for the Elderly Patients].
Izumi T; Muroi K; Hoshino Y; Komatsu N; Ohtsuki T; Yamada M; Tomizuka H; Hatake K; Furusawa S; Miura Y
Gan To Kagaku Ryoho; 1996 May; 23(6):797-800. PubMed ID: 8645033
[No Abstract] [Full Text] [Related]
12. [Results of treatment of lymphosarcoma according to the CVP program].
Shramko AF; Kruglova GV; Poddubnaia IV
Ter Arkh; 1978; 50(7):80-4. PubMed ID: 581423
[No Abstract] [Full Text] [Related]
13. [Present status and future problems in non-Hodgkin's lymphoma. III. On the chemotherapy of non-Hodgkin's lymphoma (author's transl)].
Sakano T
Rinsho Ketsueki; 1981 Feb; 22(2):159-77. PubMed ID: 7031290
[No Abstract] [Full Text] [Related]
14. [Clinical analysis of 282 patients with non-Hodgkin's lymphoma].
Chen SP; Wu DS; Zhao XL
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):237-9. PubMed ID: 14653077
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for lymphoma in a patient with common variable immunodeficiency: case report, literature review, and recommendations for chemotherapy in immunodeficient patients.
Gelmann E; Anderson T; Jaffe E; Broder S
Arch Intern Med; 1982 Jan; 142(1):90-2. PubMed ID: 7053740
[TBL] [Abstract][Full Text] [Related]
16. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
17. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy with cyclophosphamide, vincristine, and prednisone (CVP) in TNM-classified stage IV mycosis fungoides.
Tirelli U; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
Cancer Treat Rep; 1982 Jan; 66(1):167-9. PubMed ID: 7053252
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic effect of combined administration of four drugs; vincristine, bleomycin, cyclophosphamide and prednisolone for patients with malignant lymphoma (author's transl)].
Kimura I; Ohnoshi T; Nakata Y; Oka A; Hiraki S; Urabe Y; Fujii M; Hayashi K; Sato M; Kataoka M; Nishihara R; Terao S; Mito T; Tanaka T
Rinsho Ketsueki; 1980 Jun; 21(6):792-800. PubMed ID: 6162040
[No Abstract] [Full Text] [Related]
20. Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
Costello RT; Zerazhi H; Charbonnier A; de Colella JM; Alzieu C; Poizot-Martin I; Cohen R; Bardou VJ; Xerri L; Olive D; Nezri M; Lepeu G; Gastaut JA
Cancer; 2004 Feb; 100(4):667-76. PubMed ID: 14770420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
